This is the authors' abstract. We don't add key points for this paper.
Dietary fiber intake is associated with improved glycemic control in high-fat diet-induced hyperglycemia, yet the immunological mechanisms linking gut microbiota-derived metabolites to host defense remain poorly defined. Here, we investigated whether dietary fiber ameliorates these metabolic disorders by modulating intestinal group 3 innate lymphoid cells (ILC3s) via short-chain fatty acids (SCFAs) and their receptor FFAR2. In a 12-week fiber-supplemented high-fat diet mouse model, fiber alleviated hyperglycemia, insulin resistance, and intestinal barrier dysfunction. Mechanistically, fiber increased cecal SCFAs (especially propionate), which activated colonic ILC3s in an FFAR2-dependent manner. FFAR2 triggered ERK and STAT3 phosphorylation and directly bound STAT3 to facilitate its phosphorylation, boosting IL-22 transcription. SCFA-activated ILC3s strengthened epithelial barrier integrity via elevated tight-junction proteins. Collectively, our findings demonstrate that dietary fiber restores gut barrier function through the SCFA-FFAR2-ERK/STAT3-IL-22 axis in ILC 3s, highlighting ILC3-expressed FFAR2 as a potential therapeutic target for high-fat diet-related metabolic disorders.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Mou et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: